Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Icecure Medical ( (ICCM) ) has shared an update.
On November 3, 2025, IceCure Medical announced the successful results of an independent study published in PLOS One, demonstrating the effectiveness of its Cryoablation System combined with stereotactic body radiation therapy (SBRT) in treating stage I non-small cell lung cancer (NSCLC) with tumors ≥2 cm. The study, which involved 64 patients, showed a 92% disease-specific 5-year survival rate and a 74% overall survival rate, significantly higher than SBRT alone. These findings suggest that IceCure’s technology could provide a minimally invasive treatment option for inoperable NSCLC patients, potentially impacting major markets like the U.S. and Europe.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Underperform.
Icecure Medical’s overall stock score is primarily impacted by its significant financial challenges, including declining revenues and substantial losses. Technical indicators also show weak momentum, further contributing to a low score. While there is potential regulatory progress with ProSense, financial difficulties and poor valuation metrics weigh heavily on the stock’s outlook.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems that utilize liquid nitrogen to destroy tumors by freezing. The company’s primary focus areas include breast, kidney, bone, and lung cancer. IceCure’s flagship product, the ProSense® system, offers a minimally invasive alternative to surgical tumor removal and is marketed globally for approved indications.
Average Trading Volume: 1,698,000
Technical Sentiment Signal: Sell
Current Market Cap: $48.94M
Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.